Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Induction of apoptosis in fibroblasts by c-myc protein

Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M. W., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,941

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial

Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377

EGFR and cancer prognosis.

Nicholson, R., Gee, J., & Harper, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,132

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019

A small molecule–kinase interaction map for clinical kinase inhibitors

Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815

Addiction to Oncogenes--the Achilles Heal of Cancer

Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,764

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538

A Matter of Life and Cell Death

Evan, G. I., & Littlewood, T. D. (1998) · Science · doi:10.1126/science.281.5381.1317 · Cited by 1,528

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

Hirsch, F. R., Varella‐Garcia, M., Bunn, P. A., Maria, M. V. D., Veve, R., Bremnes, R. M., Barón, A. E., Zeng, C., & Franklin, W. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.069 · Cited by 1,476

Tyrosine Kinases as Targets for Cancer Therapy

Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,402

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1819 · Cited by 1,267

Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220

The new World Health Organization classification of lung tumours

Brambilla, E. M., Travis, W. D., Colby, T. V., CORRIN, B., & Shimosato, Y. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00275301 · Cited by 1,129

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Perez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M. S., Karp, D. D., Rigas, J. R., Clark, G. M., Santabarbara, P., & Bonomi, P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.057 · Cited by 1,067

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 966

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 940

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J., & Gibson, K. H. (2002) · PubMed · doi:10.7270/q2pc374f · Cited by 925

Reversible tumorigenesis by MYC in hematopoietic lineages.

Felsher, D., & Bishop, J. (1999) · Molecules and Cells · doi:10.1016/s1097-2765(00)80367-6 · Cited by 917

Essential role for oncogenic Ras in tumour maintenance

Chin, L., Tam, A., Pomerantz, J. H., Wong, M., Holash, J. A., Bardeesy, N. M., Shen, Q. “., O’Hagan, R. C., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 886

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829

The Akt-mTOR tango and its relevance to cancer

Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 826

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823

Intragenic ERBB2 kinase mutations in tumours

Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 797

EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment

Marchetti, A., Martella, C., Felicioni, L., Barassi, F., Salvatore, S., Chella, A., Camplese, P., Iarussi, T., Mucilli, F., Mezzetti, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.043 · Cited by 780

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Han, S., Kim, T., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D., Kim, J. H., Kim, D., Chung, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.388 · Cited by 757

Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 739

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

Riely, G. J., Pao, W. J., Ceppa, D. P., Li, A. R., Rizvi, N. A., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 730

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 696

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

Rapp, E., Pater, J. L., Willan, A. R., Cormier, Y. F., Murray, N., Evans, W. K., Hodson, D. I., Clark, D., Feld, R. D., & Arnold, A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.4.633 · Cited by 695

Role for c-myc in Activation-Induced Apoptotic Cell Death in T Cell Hybridomas

Shi, Y., Glynn, J. M., Guilbert, L. J., Cotter, T. G., Bissonnette, R. P., & Green, D. R. (1992) · Science · doi:10.1126/science.1378649 · Cited by 689

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

Shigematsu, H., & Gazdar, A. F. (2005) · International Journal of Cancer · doi:10.1002/ijc.21496 · Cited by 668

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 647

A loss-of-function RNA interference screen for molecular targets in cancer

Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H. G., Lenz, G., Lam, L. T., Davé, S. S., Yang, L., Powell, J. I., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 606

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 598

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 598

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Fan, Q.-W., Knight, Z. A., Goldenberg, D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 584

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Jackman, D. M., Yeap, B. Y., Sequist, L. V., Lindeman, N., Holmes, A. J., Joshi, V. A., Bell, D. W., Huberman, M. S., Halmos, B., Rabin, M. S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0462 · Cited by 584

Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes

Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582

Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study

Hirsch, F. R., Varella‐Garcia, M., McCoy, J., West, H., Xavier, A. C., Gumerlock, P. H., Bunn, P. A., Franklin, W. A., Crowley, J. J., & Gandara, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2823 · Cited by 574

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 572

Cancer revoked: oncogenes as therapeutic targets

Felsher, D. W. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1070 · Cited by 563

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 555

Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis

Reginato, M. J., Mills, K. R., Paulus, J. K., Lynch, D. K., Sgroi, D. C., Debnath, J., Muthuswamy, S. K., & Brugge, J. S. (2003) · Nature Cell Biology · doi:10.1038/ncb1026 · Cited by 545

Synergistic Augmentation of Rapamycin-Induced Autophagy in Malignant Glioma Cells by Phosphatidylinositol 3-Kinase/Protein Kinase B Inhibitors

Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G. B., & Kondo, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3640 · Cited by 545

High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan

Huang, S.-F. K., Liu, H.-P., Li, L.-H., Ku, Y.-C., Fu, Y.-N., Tsai, H., Chen, Y.-T., Lin, Y., Chang, W.-C., Kuo, H.-P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1245 · Cited by 545

Mutational Activation of the K-rasOncogene

Rodenhuis, S., van de Wetering, M. L., Mooi, W. J., Evers, S. G., van Zandwijk, N., & Bos, J. L. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171504 · Cited by 537

Requirement of NF-κB Activation to Suppress p53-Independent Apoptosis Induced by Oncogenic Ras

Mayo, M. W., Wang, C.-Y., Cogswell, P. C., Rogers-Graham, K., Lowe, S. W., Der, C. J., & Baldwin, A. S. (1997) · Science · doi:10.1126/science.278.5344.1812 · Cited by 530

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

Bell, D. W., Gore, I., Okimoto, R. A., Godin-Heymann, N., Sordella, R., Mulloy, R., Sharma, S. V., Brannigan, B. W., Mohapatra, G., Settleman, J., et al. (2005) · Nature Genetics · doi:10.1038/ng1671 · Cited by 529

Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.

Chakravarti, A., Loeffler, J. S., & Dyson, N. J. (2002) · PubMed · Cited by 509

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., & Nukiwa, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4692 · Cited by 509

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 508

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

Engelman, J. A., Janne, P. A., Mermel, C. H., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K. M., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 500

The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers

Tokumo, M., Toyooka, S., Kiura, K., Shigematsu, H., Tomii, K., Aoe, M., Ichimura, K., Tsuda, T., Yano, M., Tsukuda, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1167.11.3 · Cited by 489

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

Rusch, V. W., Baselga, J. M., Cordon‐Cardo, C., Orazem, J. P., Zaman, M., Hoda, S. A., McIntosh, J., Kurie, J. M., & Dmitrovsky, E. (1993) · PubMed · Cited by 482

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 457

Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer

Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1951 · Cited by 450

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N. X., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 449

Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib

Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. D., Gibson, N., & Sliwkowski, M. X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0453 · Cited by 445

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A. M., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 424

Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology

Janne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 413

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

Soria, J., Lee, H., Lee, J. I., Luo, W., Issa, J. J., Kemp, B. L., Liu, D. D., Kurie, J. M., Mao, L., & Khuri, F. R. (2002) · PubMed · Cited by 406

Gefitinib — a novel targeted approach to treating cancer

Herbst, R. S., Fukuoka, M., & Baselga, J. M. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1506 · Cited by 401

Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

Tracy, S. I., Mukohara, T., Hansen, M., Meyerson, M. M., Johnson, B. E., & Janne, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1905 · Cited by 372

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

Zhou, B.-B., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y. Y. C., Baribaud, F., Mikami, I., Reguart, N., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.024 · Cited by 370

Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients

Cappuzzo, F., Varella-Garcia, M., Shigematsu, H., Domenichini, I., Bartolini, S., Ceresoli, G. L., Rossi, E., Ludovini, V., Gregorc, V., Toschi, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.111 · Cited by 369

Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results

Breathnach, O. S., Freidlin, B., Conley, B. A., Green, M. R., Johnson, D. H., Gandara, D. R., O’Connell, M. J., Shepherd, F. A., & Johnson, B. E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1734 · Cited by 354

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347

Strategies to overcome resistance to targeted protein kinase inhibitors

Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 337

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Tarón, M., Ichinose, Y., Rosell, R., Mok, T. S. K., Massutí, B., Zamora, L., Mate, J. L., Manegold, C., Ono, M., Queralt, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2618 · Cited by 332

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.

Janmaat, M. L., Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2003) · PubMed · Cited by 327

Epidermal growth factor receptors in non-small cell lung cancer

Veale, D., Ashcroft, T., Marsh, C., Gibson, G., & Harris, A. L. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.104 · Cited by 326

Somatic Mutations ofEGFRin Colorectal Cancers and Glioblastomas

Barber, T. D., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412303512724 · Cited by 318

AEE788

Traxler, P. M., ALLEGRINI, P. R., Brandt, R., Brueggen, J., Cozens, R. M., Fabbro, D., Grosios, K., Lane, H. A., McSheehy, P. M. J., Mestan, J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3681 · Cited by 317

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Chou, T., Chiu, C., Li, L., Hsiao, C.-Y., Tzen, C., Chang, K.-T., Chen, Y., Perng, R.-P., Tsai, S., & Tsai, C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1981 · Cited by 315

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S. S., Lindeman, N. I., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 314

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

Hennequin, L. F., Stokes, E. S. E., Thomas, A. P., Johnstone, C., Plé, P. A., Ogilvie, D., Dukes, M., Wedge, S. R., Kendrew, J., & Curwen, J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011022e · Cited by 311

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation

Ono, M., Hirata, A., Kometani, T., Miyagawa, M., Ueda, S.-I., Kinoshita, H., Fujii, T., & Kuwano, M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.465.3.4 · Cited by 305

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

She, Q., Solit, D. B., Basso, A., & Moasser, M. M. (2003) · PubMed · Cited by 287

Regulation of cell death by the Abl tyrosine kinase

Wang, J. Y. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203878 · Cited by 279

An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor

Kobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.-K., Tenen, D. G., & Halmos, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1346 · Cited by 272

Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

Wissner, A., Overbeek, E., Reich, M. F., Floyd, M. B., Johnson, B. D., Mamuya, N. N., Rosfjord, E. C., Discafani, C. M., Davis, R. E., Shi, X., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020241c · Cited by 270

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., Lipka, E., Showalter, H. D. H., Vincent, P. W., Elliott, W. L., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990482t · Cited by 269

Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis

Weinstein, I. B. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.857 · Cited by 268

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

Ji, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A. I., Jung, B. L., McNamara, K. L., Xia, H., Glatt, K. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510284103 · Cited by 261

Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins

Shimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 260

Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

Schilder, R. J., Sill, M. W., Chen, X., Darcy, K. M., Decesare, S. L., Lewandowski, G. S., Lee, R. B., Arciero, C. A., Wu, H., & Godwin, A. K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0462 · Cited by 260

Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

Erjala, K., Sundvall, M., Junttila, T. T., Zhang, N., Savisalo, M., Mali, P., Kulmala, J. A. J., Pulkkinen, J. O., Grenman, R. A., & Elenius, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2404 · Cited by 257

Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.

Ohsaki, Y., Tanno, S., Fujita, Y., Toyoshima, E., Fujiuchi, S., Nishigaki, Y., Ishida, S., Nagase, A., Miyokawa, N., Hirata, S., et al. (2000) · Oncology Reports · doi:10.3892/or.7.3.603 · Cited by 254

ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.

Mitsudomi, T., Steinberg, S. M., Oie, H. K., Mulshine, J. L., Phelps, R. M., Viallet, J., Pass, H. I., Minna, J. D., & Gazdar, A. F. (1991) · PubMed · Cited by 248

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Goudar, R. K., Shi, Q., Hjelmeland, M. D., Keir, S. T., McLendon, R. E., Wikstrand, C. J., Reese, E. D., Conrad, C. A., Traxler, P. M., Lane, H. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.101.4.1 · Cited by 241

Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck

Lee, J. W., Soung, Y. H., Kim, S. Y., Nam, H. K., Park, W. S., Nam, S. W., Kim, M., Sun, D. I., Lee, Y. S., Jang, J. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2029 · Cited by 237

A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes

Sharma, S. V., Gajowniczek, P., Way, I., Lee, D. W., Jiang, J., Yuza, Y., Classon, M., Haber, D. A., & Settleman, J. E. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.014 · Cited by 236

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

Cortés-Funes, H., Gómez, C. G., Rosell, R., Valero, P. M., Girón, C. G., Velasco, A., Izquierdo, Á., Díz, P., Camps, C., Castellanos, D., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi221 · Cited by 229

CCI‐779 in metastatic melanoma

Margolin, K. A., Longmate, J., Baratta, T., Synold, T. W., Christensen, S., Weber, J. S., Gajewski, T. F., Quirt, I. C., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 228

Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)

Elkind, N. B., Szentpétery, Z., Apáti, Á., Özvegy‐Laczka, C., Várady, G., Ujhelly, O., Szabó, K., Homolya, L., Váradi, A., Buday, L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3303 · Cited by 223

Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.409 · Cited by 210

Gefitinib reverses breast cancer resistance protein–mediated drug resistance

Yanase, K., Tsukahara, S., Asada, S., Ishikawa, E., Imai, Y., & Sugimoto, Y. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1119.3.9 · Cited by 198

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

Anderson, N. G., Ahmad, T., Chan, K., Dobson, R., & Bundred, N. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1557 · Cited by 197

Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib

Mulloy, R., Ferrand, A., Kim, Y., Sordella, R., Bell, D. W., Haber, D. A., Anderson, K. S., & Settleman, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4293 · Cited by 192

Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90

Ge, J., Normant, E., Porter, J. R., Ali, J. A., Dembski, M. S., Gao, Y., Georges, A. T., Grenier, L., Pak, R. H., Patterson, J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603116 · Cited by 192

Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression

Jiang, J., Greulich, H. E., Janne, P. A., Sellers, W. R., Meyerson, M. M., & Griffin, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1829 · Cited by 188

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells

Kitazaki, T., Oka, M., Nakamura, Y., Tsurutani, J., Doi, S., Yasunaga, M., Takemura, M., Yabuuchi, H., Soda, H., & Kohno, S. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.03.035 · Cited by 182

Gefitinib (“Iressa”, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug Resistance

Nakamura, Y., Oka, M., Soda, H., Shiozawa, K., Yoshikawa, M., Itoh, A., Ikegami, Y., Tsurutani, J., Nakatomi, K., Kitazaki, T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-2417 · Cited by 179

EGFRMutation Conferring Primary Resistance to Gefitinib in Non–Small-Cell Lung Cancer

Shih, J., Gow, C., & Yang, P. (2005) · New England Journal of Medicine · doi:10.1056/nejm200507143530217 · Cited by 177

Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer

Kim, K., Jeong, J.-Y., Kim, Y., Na, K.-J., Kim, Y., Ahn, S., Baek, S.-M., Park, C.-S., Park, C.-M., Kim, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2081 · Cited by 168

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

Doherty, L. M., Gigas, D. C., Kesari, S., Drappatz, J., Kim, R., Zimmerman, J., Ostrowsky, L., & Wen, P. Y. (2006) · Neurology · doi:10.1212/01.wnl.0000223844.77636.29 · Cited by 166

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study

Niho, S., Kubota, K., Goto, K., Yoh, K., Ohmatsu, H., Kakinuma, R., Saijo, N., & Nishiwaki, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5825 · Cited by 159

Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas

Kwak, E. L., Jankowski, J. A., Thayer, S. P., Lauwers, G. Y., Brannigan, B. W., Harris, P. L., Okimoto, R. A., Haserlat, S. M., Driscoll, D. R., Ferry, D. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0189 · Cited by 156

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Ihle, N. T., Paine-Murrieta, G. D., Berggren, M. I., Baker, A. F., Tate, W. R., Wipf, P., Abraham, R. T., Kirkpatrick, D. L., & Powis, G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0149 · Cited by 154

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer

Han, S., Hwang, P. G., Chung, D. H., Kim, D., Im, S., Kim, Y. T., Kim, T., Heo, D. S., Bang, Y., & Kim, N. K. (2004) · International Journal of Cancer · doi:10.1002/ijc.20550 · Cited by 150

Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib

Koizumi, F., Shimoyama, T., Taguchi, F., Saijo, N., & Nishio, K. (2005) · International Journal of Cancer · doi:10.1002/ijc.20985 · Cited by 147

Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors

Blencke, S., Zech, B., Engkvist, O., Greff, Z., Őrfi, L., Horváth, Z., Kéri, G., Ullrich, A., & Daub, H. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.029 · Cited by 145

K‐ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos

Husgafvel‐Pursiainen, K., Hackman, P., Ridanpää, M., Anttila, S. L., Karjalainen, A., Partanen, T. J., Taikina-aho, O., Heikkilä, L. J., & Vainio, H. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530213 · Cited by 145

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters

Özvegy‐Laczka, C., Cserepes, J., Elkind, N. B., & Sarkadi, B. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.02.002 · Cited by 144

Inactivation of thePTEN/MMAC1/TEP1 gene in human lung cancers

Kohno, T., Takahashi, M., Manda, R., & Yokota, J. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199806)22:2 · Cited by 142

Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272

Shimamura, T., Ji, H., Minami, Y., Thomas, R. K., Lowell, A. M., Shah, K., Greulich, H. E., Glatt, K. A., Meyerson, M. M., Shapiro, G. I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0971 · Cited by 135

Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2.

Chen, C. Y., & Faller, D. V. (1995) · PubMed · Cited by 133

Clinicopathologic Significance of the Mutations of theEpidermal Growth Factor ReceptorGene in Patients with Non–Small Cell Lung Cancer

Tomizawa, Y., Iijima, H., Sunaga, N., Sato, K., Takise, A., Otani, Y., Tanaka, S., Suga, T., Saito, R., Ishizuka, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0441 · Cited by 129

Where next for gefitinib in patients with lung cancer?

Blackhall, F. H., Ranson, M., & Thatcher, N. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70725-2 · Cited by 123

Epidermal growth factor receptor expression in human lung cancer cell lines

Medicine, I. (1989) · Lung Cancer · doi:10.1016/0169-5002(89)90348-6 · Cited by 121

Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer

Mu, X. L., Li, L. Y., Zhang, X. T., Wang, M. Z., Feng, R. E., Cui, Q. C., Zhou, H., & Guo, B. Q. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2506 · Cited by 118

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

Discafani, C. M., Carroll, M. L., Floyd, M. B., Hollander, I. J., Husain, Z., Johnson, B. D., Kitchen, D., May, M. K., Malo, M. S., Minnick, A. A., et al. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00356-6 · Cited by 112

Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases

Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara, D. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960380s · Cited by 108

EGFR mutation in gefitinib-responsive small-cell lung cancer

Okamoto, I., Araki, J., Suto, R., Shimada, M., Nakagawa, K., & Fukuoka, M. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj114 · Cited by 108

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas

Gwak, G., Yoon, J., Shin, C. M., Ahn, Y. J., Chung, J., Kim, Y. A., Kim, T., & Lee, H. S. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0016-1 · Cited by 108

Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines

Hurbin, A., Dubrez, L., Coll, J., & Favrot, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207584200 · Cited by 102

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib

Cappuzzo, F., Toschi, L., Tallini, G., Ceresoli, G. L., Domenichini, I., Bartolini, S., Finocchiaro, G., Magrini, E., Metro, G., Cancellieri, A., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl077 · Cited by 97

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas

Soung, Y. H., Lee, J. W., Kim, S. Y., Seo, S. H., Park, W. S., Nam, S. W., Song, S. Y., Han, J. H., Park, C. K., Lee, J. Y., et al. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1254-y · Cited by 97

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

Zhang, X.-T., Li, L.-Y., Mu, X. L., Cui, Q.-C., Chang, X.-Y., Song, W., Wang, S., Wang, M., Zhong, W., & Zhang, L. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi340 · Cited by 96

Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells

Rao, R. D., Mladek, A. C., Lamont, J. D., Goble, J. M., Erlichman, C., James, C. D., & Sarkaria, J. N. (2005) · Neoplasia · doi:10.1593/neo.05361 · Cited by 95

Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein

Yang, C.-H., Huang, C.-J., Yang, C.-S., Chu, Y.-C., Cheng, A., Whang‐Peng, J., & Yang, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0641 · Cited by 95

Therapeutic potential of target of rapamycin inhibitors

Easton, J. B., & Houghton, P. J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.6.551 · Cited by 84

Regulation of both apoptosis and cell survival by the v-Src oncoprotein

Johnson, D., Agochiya, M., Samejima, K., Earnshaw, W. C., Frame, M. C., & Wyke, J. A. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400700 · Cited by 82

Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors

Yang, S., Qu, S., Perez-Tores, M., Sawai, A., Rosen, N. X., Solit, D. B., & Arteaga, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1042 · Cited by 81

Epidermal Growth Factor ReceptorMutation Testing in the Care of Lung Cancer Patients

Sequist, L. V. D., Joshi, V. A., Janne, P. A., Bell, D. W., Fidias, P. M., Lindeman, N. I., Louis, D. N., Lee, J. C., Mark, E. J., Longtine, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0099 · Cited by 81

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

Cappuzzo, F., Toschi, L., Domenichini, I., Bartolini, S., Ceresoli, G. L., Rossi, E., Ludovini, V., Cancellieri, A., Magrini, E., Bemis, L., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602865 · Cited by 77

Chromosome abnormalities in human non-small cell lung cancer.

Testa, J. R., & Siegfried, J. M. (1992) · PubMed · Cited by 74

Expression of adenovirus E1B mutant phenotypes is dependent on the host cell and on synthesis of E1A proteins

White, E., & Stillman, B. (1987) · Journal of Virology · doi:10.1128/jvi.61.2.426-435.1987 · Cited by 72

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

Rosell, R., Ichinose, Y., Tarón, M., Sarries, C., Queralt, C., Méndez, P., Sánchez, J. M., Nishiyama, K., Morán, T., Cirauqui, B., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.05.017 · Cited by 71

A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma

Haneda, H., Sasaki, H., Lindeman, N. I., Kawano, O., Endo, K., Suzuki, E., Shimizu, S., Yukiue, H., Kobayashi, Y., Yano, M., et al. (2006) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyi228 · Cited by 65

Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.

Mendelsohn, J. M. (1992) · PubMed · Cited by 64

Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L

Asahina, H., Yamazaki, K., Kinoshita, I., Yokouchi, H., Dosaka-Akita, H., & Nishimura, M. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.09.005 · Cited by 63

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer

Tokumo, M., Toyooka, S., Ichihara, S., Ohashi, K., Tsukuda, K., Ichimura, K., Tabata, M., Kiura, K., Aoe, M., Sano, Y., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.04.008 · Cited by 61

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models

Taguchi, F., Koh, Y., Koizumi, F., Tamura, T., Saijo, N., & Nishio, K. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03187.x · Cited by 60

v-Src Generates a p53-Independent Apoptotic Signal

Webb, B. L., Jimenez, E., & Martin, G. S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9271-9280.2000 · Cited by 53

Autocrine growth stimulation by transforming growth factor-α in human non-small cell lung cancer

Putnam, E. A., Yen, N., Gallick, G. E., Steck, P. A., Fang, K., Akpakip, B., Gazdar, A. F., & Roth, J. A. (1992) · Surgical Oncology · doi:10.1016/0960-7404(92)90056-q · Cited by 49

Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting

Sallah, S., Wan, J. Y., Nguyen, N. P., Vos, P. W., & Sigounas, G. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 47

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer

Nagashima, S., Soda, H., Oka, M., Kitazaki, T., Shiozawa, K., Nakamura, Y., Takemura, M., Yabuuchi, H., Fukuda, M., Tsukamoto, K., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0212-y · Cited by 41

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer

on behalf of the Central Japan Lung Study Group, Suzuki, R., Hasegawa, Y., Baba, K., Saka, H., Saito, H., Taniguchi, H., Yamamoto, M., Matsumoto, S., Kato, K., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603159 · Cited by 41

Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition

Adjei, A. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0623 · Cited by 39

Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer

Blackhall, F. H., Shepherd, F. A., & Albain, K. S. (2005) · Treatments in Respiratory Medicine · doi:10.2165/00151829-200504020-00001 · Cited by 38

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery

Kondo, M., Yokoyama, T., Fukui, T., Yoshioka, H., Yokoi, K., Nagasaka, T., Imaizumi, K., Kume, H., Hasegawa, Y., Shimokata, K., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.06.008 · Cited by 38

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications

Prudkin, L., & Wistuba, I. I. (2006) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2006.06.011 · Cited by 30

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R

Gow, C., Shih, J., Chang, Y., & Yu, C. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020269 · Cited by 28

Phase II Data with ZD6474, a Small-Molecule Kinase Inhibitor of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor, in Previously Treated Advanced Non–Small-Cell Lung Cancer

Lee, D. S., Natale, R. B., Nadler, E., & Jain, V. K. (2005) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70394-1 · Cited by 23

The Gefitinib-Sensitizing Mutant Epidermal Growth Factor Receptor Enables Transformation of a Mouse Fibroblast Cell Line

Nagatomo, I., Kumagai, T., Yamadori, T., Furukawa, M., Takahashi, R., Yoneda, T., Ogata, Y., Saito, Y., Inoue, K., Yano, Y., et al. (2006) · DNA and Cell Biology · doi:10.1089/dna.2006.25.246 · Cited by 14

Overcoming Acquired Resistance to Iressa/Tarceva with Inhibitors of a Different Class

Haber, D. A., & Settleman, J. E. (2005) · Cell Cycle · doi:10.4161/cc.4.8.1874 · Cited by 13

Mutated kinases as targets for cancer drugs

Settleman, J. E. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.05.006 · Cited by 7

Cell Signaling by Receptor Tyrosine Kinases

Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

The biology and management of non-small cell lung cancer

Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228

Metastasis: from dissemination to organ-specific colonization

Nguyen, D. X., Bos, P. D., & Massagué, J. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2622 · Cited by 2,716

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156